Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Ингибиторы ангиотензинпревращающего фермента, риск деменции и возможности улучшения когнитивных функций: уникальные особенности периндоприла
Ингибиторы ангиотензинпревращающего фермента, риск деменции и возможности улучшения когнитивных функций: уникальные особенности периндоприла
Остроумова О.Д., Галеева Н.Ю., Бондарец О.В. и др. Ингибиторы ангиотензинпревращающего фермента, риск деменции и возможности улучшения когнитивных функций: уникальные особенности периндоприла. Consilium Medicum. 2016; 18 (1): 67–72. DOI: 10.26442/2075-1753_2016.1.67-72
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье рассмотрены возможности 5 основных классов антигипертензивных препаратов в снижении риска деменции и влиянии на состояние когнитивных функций. Констатируется, что ингибиторы ангиотензинпревращающего фермента не имеют класс-эффекта в отношении церебропротекции. Подробно рассмотрены имеющиеся данные о способности периндоприла в профилактике деменции и улучшении когнитивных функций. Обсуждаются возможные механизмы церебропротективного действия периндоприла.
Ключевые слова: когнитивные функции, когнитивные нарушения, деменция, артериальная гипертония, антигипертензивные препараты, ингибиторы ангиотензинпревращающего фермента, периндоприл.
Key words: cognitive functions, cognitive impairments, dementia, arterial hypertension, antihypertensive drugs, angiotensin-converting enzyme inhibitors, perindopril.
Ключевые слова: когнитивные функции, когнитивные нарушения, деменция, артериальная гипертония, антигипертензивные препараты, ингибиторы ангиотензинпревращающего фермента, периндоприл.
________________________________________________
Key words: cognitive functions, cognitive impairments, dementia, arterial hypertension, antihypertensive drugs, angiotensin-converting enzyme inhibitors, perindopril.
Полный текст
Список литературы
1. Захаров В.В., Локшина А.Б. Когнитивные нарушения в общеклинической практике. М., 2009. / Zakharov V.V., Lokshina A.B. Kognitivnye narusheniia v obshcheklinicheskoi praktike. M., 2009. [in Russian]
2. Larrieu S, Letenneur L, Orgogozo JM. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 2002; 59: 1594–9.
3. Левин О.С. Диагностика и лечение деменции в клинической практике. М.: МЕДпресс-информ, 2010. / Levin O.S. Diagnostika i lechenie dementsii v klinicheskoi praktike. M.: MEDpress-inform, 2010. [in Russian]
4. Диагностика и лечение артериальной гипертензии. Системные гипертензии. 2010; 6 (3): 5–26. / Diagnostika i lechenie arterial'noi gipertenzii. Systemic Hypertension. 2010; 6 (3): 5–26. [in Russian]
5. Henderson AS. Dementia. World Health Organization, Geneva, 1994.
6. Amaducci L, Andrea L. The epidemiology of the dementia in Europe. In: A.Culebras, J.Matias Cuiu, G.Roman (eds): New concepts in vascular dementia. Barselona: Prous Science Publishers, 1993; p. 1927.
7. Skoog I, Lernfelt B, Landahl S et al. 15-years longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141–5.
8. Launer LJ, Masaki K, Petrovitch H et al. The assotiation between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995; 274: 1846–51.
9. Singh-Manoux A, Marmot M. High blood pressure was associated with cognitive function in middle-age in the Whitehall II study J. Clin Epidemiol 2005; 58: 1308–15.
10. Forette F, Seux M-L, Staessen JA et al. for the Syst-Eur Investigators. The Prevention of Dementia with Antihypertensive Treatment. New evidence from the Systolic Hypertension (Syst-Eur) Study. Arch Intern Med 2002; 162 (18): 2046–52.
11. Lithell H, Hansson L, Skoog I et al; SCOPE Study Group. The study on cognition and prognosis in the elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21: 875–86.
12. PROGRESS collaborative study group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
13. Marpillat NL, Macquin-Mavier I, Tropeano A-I et al. Antihypertensive classes, cognitive decline andincidence of dementia: a networkmeta-analysis. J Hypertens 2013, 31 (6): 1073–82.
14. Chiu W-C, Ho W-C, Lin M-H et al; Health Data Analysis in Taiwan (hDATa) Research Group. Angiotension receptor blockers reduce the risk of dementia. J Hypertens 2014, 32: 938–47.
15. The Progress Collaborative Group. Еffects of blood pressure lowering with perindopril and indapamade therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Int Med 2003;163: 1069–75.
16. Левин О.С., Дамулин И.В. Диффузные изменения белого вещества (лейкоареоз) и проблема сосудистой деменции. В кн.: Достижения в нейрогериатрии. Под ред. Н.Н.Яхно, И.В.Дамулина. Ч. 2. М., 1995; с. 189–231. / Levin O.S., Damulin I.V. Diffuznye izmeneniia belogo veshchestva (leikoareoz) i problema sosudistoi dementsii. V kn.: Dostizheniia v neirogeriatrii. Pod red. N.N.Iakhno, I.V.Damulina. Ch. 2. M., 1995; s. 189–231. [in Russian]
17. Dufouil С, Chalmers J, Coskun O. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005; 112 (1l): 1644–50.
18. Остроумова О.Д., Десницкая И.В. Подходы к лечению артериальной гипертонии в условиях стационара: коррекция артериального давления и состояние когнитивных функций. Системные гипертензии. 2005; 1 (2): 14–7. / Ostroumova O.D., Desnitskaia I.V. Podkhody k lecheniiu arterial'noi gipertonii v usloviiakh statsionara: korrektsiia arterial'nogo davleniia i sostoianie kognitivnykh funktsii. Systemic Hypertension. 2005; 1 (2): 14–7. [in Russian]
19. Морозова Т.Е., Гонтаренко С.В. Влияние антигипертензивных препаратов на состояние когнитивных функций у больных артериальной гипертензией I–II степени. Лечащий врач. 2014; 7: 15–9. / Morozova T.E., Gontarenko S.V. Vliianie antigipertenzivnykh preparatov na sostoianie kognitivnykh funktsii u bol'nykh arterial'noi gipertenziei I–II stepeni. Lechashchii vrach. 2014; 7: 15–9. [in Russian]
20. Fogari R, Mugellini A, Zoppi A et al. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur. J Clin Pharmacol 2004; 59: 863–8.
21. Sink КМ, Leng Х, Williamson J et al. Angiotensin Converting Enzyme Inhibitors and Cognitive Decline in Older Adults with Hypertension: Results from the Cardiovascular Health Study. Arch Intern Med 2009; 169 (13): 1195–202.
22. Ohrui T, Tomita N, Sato-Nakagawa T et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004; 63: 1324–5.
23. Pihlaja R, Kauppinen R, Koistinaho J, Koistinaho M. Multiple cellular and molecular mechanisms are involved in human Ab clearance by transplanted adult astrocytes. Glia 2011; 59 (11): 1643–57.
24. Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer’s disease? Lancet Neurol 2007; 6 (4): 373–8.
25. Phillips MI, de Oliveira EM. Brain renin angiotensin in disease. J Mol Med 2008; 86 (6): 715–22.
26. Ciobica A, Bild W, Hritcu L, Haulica I. Brain renin-angiotensin system in cognitive function: pre-clinical findings and implications for prevention and treatment of dementia. Acta Neurol Belg 2009; 109 (3): 171–80.
27. Savaskan E, Hock C, Olivieri G et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer’s dementia. Neurobiol Aging 2001; 22 (4): 541–6.
28. Ferrari R, Pasanisi G, Notasrstefano P et al. Specific properties and effect of perindopril in controlling the renin-angiotensin system. Am J Hypertens 2005; 18: 142–54.
2. Larrieu S, Letenneur L, Orgogozo JM. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 2002; 59: 1594–9.
3. Levin O.S. Diagnostika i lechenie dementsii v klinicheskoi praktike. M.: MEDpress-inform, 2010. [in Russian]
4. Diagnostika i lechenie arterial'noi gipertenzii. Systemic Hypertension. 2010; 6 (3): 5–26. [in Russian]
5. Henderson AS. Dementia. World Health Organization, Geneva, 1994.
6. Amaducci L, Andrea L. The epidemiology of the dementia in Europe. In: A.Culebras, J.Matias Cuiu, G.Roman (eds): New concepts in vascular dementia. Barselona: Prous Science Publishers, 1993; p. 1927.
7. Skoog I, Lernfelt B, Landahl S et al. 15-years longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141–5.
8. Launer LJ, Masaki K, Petrovitch H et al. The assotiation between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995; 274: 1846–51.
9. Singh-Manoux A, Marmot M. High blood pressure was associated with cognitive function in middle-age in the Whitehall II study J. Clin Epidemiol 2005; 58: 1308–15.
10. Forette F, Seux M-L, Staessen JA et al. for the Syst-Eur Investigators. The Prevention of Dementia with Antihypertensive Treatment. New evidence from the Systolic Hypertension (Syst-Eur) Study. Arch Intern Med 2002; 162 (18): 2046–52.
11. Lithell H, Hansson L, Skoog I et al; SCOPE Study Group. The study on cognition and prognosis in the elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21: 875–86.
12. PROGRESS collaborative study group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
13. Marpillat NL, Macquin-Mavier I, Tropeano A-I et al. Antihypertensive classes, cognitive decline andincidence of dementia: a networkmeta-analysis. J Hypertens 2013, 31 (6): 1073–82.
14. Chiu W-C, Ho W-C, Lin M-H et al; Health Data Analysis in Taiwan (hDATa) Research Group. Angiotension receptor blockers reduce the risk of dementia. J Hypertens 2014, 32: 938–47.
15. The Progress Collaborative Group. Еffects of blood pressure lowering with perindopril and indapamade therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Int Med 2003;163: 1069–75.
16. Levin O.S., Damulin I.V. Diffuznye izmeneniia belogo veshchestva (leikoareoz) i problema sosudistoi dementsii. V kn.: Dostizheniia v neirogeriatrii. Pod red. N.N.Iakhno, I.V.Damulina. Ch. 2. M., 1995; s. 189–231. [in Russian]
17. Dufouil С, Chalmers J, Coskun O. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005; 112 (1l): 1644–50.
18. Ostroumova O.D., Desnitskaia I.V. Podkhody k lecheniiu arterial'noi gipertonii v usloviiakh statsionara: korrektsiia arterial'nogo davleniia i sostoianie kognitivnykh funktsii. Systemic Hypertension. 2005; 1 (2): 14–7. [in Russian]
19. Morozova T.E., Gontarenko S.V. Vliianie antigipertenzivnykh preparatov na sostoianie kognitivnykh funktsii u bol'nykh arterial'noi gipertenziei I–II stepeni. Lechashchii vrach. 2014; 7: 15–9. [in Russian]
20. Fogari R, Mugellini A, Zoppi A et al. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur. J Clin Pharmacol 2004; 59: 863–8.
21. Sink КМ, Leng Х, Williamson J et al. Angiotensin Converting Enzyme Inhibitors and Cognitive Decline in Older Adults with Hypertension: Results from the Cardiovascular Health Study. Arch Intern Med 2009; 169 (13): 1195–202.
22. Ohrui T, Tomita N, Sato-Nakagawa T et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004; 63: 1324–5.
23. Pihlaja R, Kauppinen R, Koistinaho J, Koistinaho M. Multiple cellular and molecular mechanisms are involved in human Ab clearance by transplanted adult astrocytes. Glia 2011; 59 (11): 1643–57.
24. Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer’s disease? Lancet Neurol 2007; 6 (4): 373–8.
25. Phillips MI, de Oliveira EM. Brain renin angiotensin in disease. J Mol Med 2008; 86 (6): 715–22.
26. Ciobica A, Bild W, Hritcu L, Haulica I. Brain renin-angiotensin system in cognitive function: pre-clinical findings and implications for prevention and treatment of dementia. Acta Neurol Belg 2009; 109 (3): 171–80.
27. Savaskan E, Hock C, Olivieri G et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer’s dementia. Neurobiol Aging 2001; 22 (4): 541–6.
28. Ferrari R, Pasanisi G, Notasrstefano P et al. Specific properties and effect of perindopril in controlling the renin-angiotensin system. Am J Hypertens 2005; 18: 142–54.
2. Larrieu S, Letenneur L, Orgogozo JM. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 2002; 59: 1594–9.
3. Левин О.С. Диагностика и лечение деменции в клинической практике. М.: МЕДпресс-информ, 2010. / Levin O.S. Diagnostika i lechenie dementsii v klinicheskoi praktike. M.: MEDpress-inform, 2010. [in Russian]
4. Диагностика и лечение артериальной гипертензии. Системные гипертензии. 2010; 6 (3): 5–26. / Diagnostika i lechenie arterial'noi gipertenzii. Systemic Hypertension. 2010; 6 (3): 5–26. [in Russian]
5. Henderson AS. Dementia. World Health Organization, Geneva, 1994.
6. Amaducci L, Andrea L. The epidemiology of the dementia in Europe. In: A.Culebras, J.Matias Cuiu, G.Roman (eds): New concepts in vascular dementia. Barselona: Prous Science Publishers, 1993; p. 1927.
7. Skoog I, Lernfelt B, Landahl S et al. 15-years longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141–5.
8. Launer LJ, Masaki K, Petrovitch H et al. The assotiation between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995; 274: 1846–51.
9. Singh-Manoux A, Marmot M. High blood pressure was associated with cognitive function in middle-age in the Whitehall II study J. Clin Epidemiol 2005; 58: 1308–15.
10. Forette F, Seux M-L, Staessen JA et al. for the Syst-Eur Investigators. The Prevention of Dementia with Antihypertensive Treatment. New evidence from the Systolic Hypertension (Syst-Eur) Study. Arch Intern Med 2002; 162 (18): 2046–52.
11. Lithell H, Hansson L, Skoog I et al; SCOPE Study Group. The study on cognition and prognosis in the elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21: 875–86.
12. PROGRESS collaborative study group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
13. Marpillat NL, Macquin-Mavier I, Tropeano A-I et al. Antihypertensive classes, cognitive decline andincidence of dementia: a networkmeta-analysis. J Hypertens 2013, 31 (6): 1073–82.
14. Chiu W-C, Ho W-C, Lin M-H et al; Health Data Analysis in Taiwan (hDATa) Research Group. Angiotension receptor blockers reduce the risk of dementia. J Hypertens 2014, 32: 938–47.
15. The Progress Collaborative Group. Еffects of blood pressure lowering with perindopril and indapamade therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Int Med 2003;163: 1069–75.
16. Левин О.С., Дамулин И.В. Диффузные изменения белого вещества (лейкоареоз) и проблема сосудистой деменции. В кн.: Достижения в нейрогериатрии. Под ред. Н.Н.Яхно, И.В.Дамулина. Ч. 2. М., 1995; с. 189–231. / Levin O.S., Damulin I.V. Diffuznye izmeneniia belogo veshchestva (leikoareoz) i problema sosudistoi dementsii. V kn.: Dostizheniia v neirogeriatrii. Pod red. N.N.Iakhno, I.V.Damulina. Ch. 2. M., 1995; s. 189–231. [in Russian]
17. Dufouil С, Chalmers J, Coskun O. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005; 112 (1l): 1644–50.
18. Остроумова О.Д., Десницкая И.В. Подходы к лечению артериальной гипертонии в условиях стационара: коррекция артериального давления и состояние когнитивных функций. Системные гипертензии. 2005; 1 (2): 14–7. / Ostroumova O.D., Desnitskaia I.V. Podkhody k lecheniiu arterial'noi gipertonii v usloviiakh statsionara: korrektsiia arterial'nogo davleniia i sostoianie kognitivnykh funktsii. Systemic Hypertension. 2005; 1 (2): 14–7. [in Russian]
19. Морозова Т.Е., Гонтаренко С.В. Влияние антигипертензивных препаратов на состояние когнитивных функций у больных артериальной гипертензией I–II степени. Лечащий врач. 2014; 7: 15–9. / Morozova T.E., Gontarenko S.V. Vliianie antigipertenzivnykh preparatov na sostoianie kognitivnykh funktsii u bol'nykh arterial'noi gipertenziei I–II stepeni. Lechashchii vrach. 2014; 7: 15–9. [in Russian]
20. Fogari R, Mugellini A, Zoppi A et al. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur. J Clin Pharmacol 2004; 59: 863–8.
21. Sink КМ, Leng Х, Williamson J et al. Angiotensin Converting Enzyme Inhibitors and Cognitive Decline in Older Adults with Hypertension: Results from the Cardiovascular Health Study. Arch Intern Med 2009; 169 (13): 1195–202.
22. Ohrui T, Tomita N, Sato-Nakagawa T et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004; 63: 1324–5.
23. Pihlaja R, Kauppinen R, Koistinaho J, Koistinaho M. Multiple cellular and molecular mechanisms are involved in human Ab clearance by transplanted adult astrocytes. Glia 2011; 59 (11): 1643–57.
24. Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer’s disease? Lancet Neurol 2007; 6 (4): 373–8.
25. Phillips MI, de Oliveira EM. Brain renin angiotensin in disease. J Mol Med 2008; 86 (6): 715–22.
26. Ciobica A, Bild W, Hritcu L, Haulica I. Brain renin-angiotensin system in cognitive function: pre-clinical findings and implications for prevention and treatment of dementia. Acta Neurol Belg 2009; 109 (3): 171–80.
27. Savaskan E, Hock C, Olivieri G et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer’s dementia. Neurobiol Aging 2001; 22 (4): 541–6.
28. Ferrari R, Pasanisi G, Notasrstefano P et al. Specific properties and effect of perindopril in controlling the renin-angiotensin system. Am J Hypertens 2005; 18: 142–54.
________________________________________________
2. Larrieu S, Letenneur L, Orgogozo JM. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 2002; 59: 1594–9.
3. Levin O.S. Diagnostika i lechenie dementsii v klinicheskoi praktike. M.: MEDpress-inform, 2010. [in Russian]
4. Diagnostika i lechenie arterial'noi gipertenzii. Systemic Hypertension. 2010; 6 (3): 5–26. [in Russian]
5. Henderson AS. Dementia. World Health Organization, Geneva, 1994.
6. Amaducci L, Andrea L. The epidemiology of the dementia in Europe. In: A.Culebras, J.Matias Cuiu, G.Roman (eds): New concepts in vascular dementia. Barselona: Prous Science Publishers, 1993; p. 1927.
7. Skoog I, Lernfelt B, Landahl S et al. 15-years longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141–5.
8. Launer LJ, Masaki K, Petrovitch H et al. The assotiation between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995; 274: 1846–51.
9. Singh-Manoux A, Marmot M. High blood pressure was associated with cognitive function in middle-age in the Whitehall II study J. Clin Epidemiol 2005; 58: 1308–15.
10. Forette F, Seux M-L, Staessen JA et al. for the Syst-Eur Investigators. The Prevention of Dementia with Antihypertensive Treatment. New evidence from the Systolic Hypertension (Syst-Eur) Study. Arch Intern Med 2002; 162 (18): 2046–52.
11. Lithell H, Hansson L, Skoog I et al; SCOPE Study Group. The study on cognition and prognosis in the elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21: 875–86.
12. PROGRESS collaborative study group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
13. Marpillat NL, Macquin-Mavier I, Tropeano A-I et al. Antihypertensive classes, cognitive decline andincidence of dementia: a networkmeta-analysis. J Hypertens 2013, 31 (6): 1073–82.
14. Chiu W-C, Ho W-C, Lin M-H et al; Health Data Analysis in Taiwan (hDATa) Research Group. Angiotension receptor blockers reduce the risk of dementia. J Hypertens 2014, 32: 938–47.
15. The Progress Collaborative Group. Еffects of blood pressure lowering with perindopril and indapamade therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Int Med 2003;163: 1069–75.
16. Levin O.S., Damulin I.V. Diffuznye izmeneniia belogo veshchestva (leikoareoz) i problema sosudistoi dementsii. V kn.: Dostizheniia v neirogeriatrii. Pod red. N.N.Iakhno, I.V.Damulina. Ch. 2. M., 1995; s. 189–231. [in Russian]
17. Dufouil С, Chalmers J, Coskun O. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005; 112 (1l): 1644–50.
18. Ostroumova O.D., Desnitskaia I.V. Podkhody k lecheniiu arterial'noi gipertonii v usloviiakh statsionara: korrektsiia arterial'nogo davleniia i sostoianie kognitivnykh funktsii. Systemic Hypertension. 2005; 1 (2): 14–7. [in Russian]
19. Morozova T.E., Gontarenko S.V. Vliianie antigipertenzivnykh preparatov na sostoianie kognitivnykh funktsii u bol'nykh arterial'noi gipertenziei I–II stepeni. Lechashchii vrach. 2014; 7: 15–9. [in Russian]
20. Fogari R, Mugellini A, Zoppi A et al. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur. J Clin Pharmacol 2004; 59: 863–8.
21. Sink КМ, Leng Х, Williamson J et al. Angiotensin Converting Enzyme Inhibitors and Cognitive Decline in Older Adults with Hypertension: Results from the Cardiovascular Health Study. Arch Intern Med 2009; 169 (13): 1195–202.
22. Ohrui T, Tomita N, Sato-Nakagawa T et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004; 63: 1324–5.
23. Pihlaja R, Kauppinen R, Koistinaho J, Koistinaho M. Multiple cellular and molecular mechanisms are involved in human Ab clearance by transplanted adult astrocytes. Glia 2011; 59 (11): 1643–57.
24. Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer’s disease? Lancet Neurol 2007; 6 (4): 373–8.
25. Phillips MI, de Oliveira EM. Brain renin angiotensin in disease. J Mol Med 2008; 86 (6): 715–22.
26. Ciobica A, Bild W, Hritcu L, Haulica I. Brain renin-angiotensin system in cognitive function: pre-clinical findings and implications for prevention and treatment of dementia. Acta Neurol Belg 2009; 109 (3): 171–80.
27. Savaskan E, Hock C, Olivieri G et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer’s dementia. Neurobiol Aging 2001; 22 (4): 541–6.
28. Ferrari R, Pasanisi G, Notasrstefano P et al. Specific properties and effect of perindopril in controlling the renin-angiotensin system. Am J Hypertens 2005; 18: 142–54.
Авторы
О.Д.Остроумова*1,2, Н.Ю.Галеева1, О.В.Бондарец1, Т.Ф.Гусева1, И.И.Копченов1
1 ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
2 ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*ostroumova.olga@mail.ru
1 A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
2 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*ostroumova.olga@mail.ru
1 ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
2 ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*ostroumova.olga@mail.ru
________________________________________________
1 A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
2 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*ostroumova.olga@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.